Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasHodgkin LymphomaIndolent LymphomasTransplantationDiseaseAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C83.7C84.4C88.0-C91.0-C91.1-MeSHLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)ChemotherapyChemo-substanceBendamustineCarboplatinCarmustineCytarabineDexamethasoneEtoposideMelphalanMosunetuzumabRituximabChemo-substanceBendamustineCarboplatinCarmustineCytarabineDexamethasoneEtoposideMelphalanMosunetuzumabRituximabChemo-substanceBendamustineCarboplatinCarmustineCytarabineDexamethasoneEtoposideMelphalanMosunetuzumabRituximabChemo-substanceBendamustineCarboplatinCarmustineCytarabineDexamethasoneEtoposideMelphalanMosunetuzumabRituximabNo. Substances1346 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances3567Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseInductionSalvageTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlCytokine Release SyndromeDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHyperglycemiaHypertensionHypokalemiaHypophosphatemiaIncrease AminotransferasesInfectionsNeuropathyNeutropeniaPneumoniaRashSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBudde LEDavies AKirschey STessoulin BDiseaseB-Non-Hodgkin-Lymphom/Hodgkin LymphomNon-Hodgkin-Lymphom / Hodgkin LymphomRefraktäres oder rezidivierendes Non-Hodgkin-Lymphomrezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2rezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenOriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCity of Hope National Medical Center, Duarte, CADepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USANantes Medical University, Nantes, FranceProtocols in Revision 8 protocols foundProtocols under revision.DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105 V1.0)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107 V1.0)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Rituximab 375 / Bendamustine 120 / Carboplatin 5 / Etoposide 100, B-Non-Hodgkin Lymphoma. (PID2390 V1.0)
